The AV backbone for the AQP1 sense (s) and antisense
(as) AV constructs was a replication-deficient first-generation AV with
deletions of the
E1 and
E3 genes.
20 This empty AV contains the cytomegalovirus (CMV) promoter and bovine
growth hormone polyadenylation (bGH) site separated by a polylinker
containing a unique
XbaI restriction site. A large-scale
preparation of empty AV DNA (described later) was digested with
proteinase K (Sigma, St. Louis, MO) in the presence of 0.5% SDS at
55°C for 2 hours, followed by phenol-chloroform (1:1, vol/vol)
extraction and ethanol precipitation. Viral DNA was then restricted
with
XbaI overnight, and the large fragment containing the
bGH and AV (map units 9.3-100) was gel purified from a 0.6% agarose
gel. This DNA fragment served as the right end of both AQP1(s) AV
constructs.
The left ends of AQP1 recombinant viruses were constructed uniquely
(see
Fig. 1 ). For AQP1(s) AV, a plasmid containing the coding sequence
for AQP1, pCHIPev,
21 was digested with
KpnI and
BamHI (giving a 1162-bp fragment) and subcloned into the
shuttle vector pSKAC, creating pSKAC/AQP1. pSKAC contains the left end
cassette (map units 0.0-1.3) of the AV that is flanked by two unique
restriction sites,
PmeI and
XbaI. The cassette
includes the left terminal repeat of AV, a CMV promoter, an AMV
translation enhancer, and a polylinker region.
An 807-bp DNA fragment encoding AQP1(as) was generated by PCR, with
pCHIPev used as a template and primers that delineated the full coding
sequence of AQP1: 5′-CGCGAATTCCTATTTGGGCTTCATCTC-3′ and
5′-CGCGGATCCATGGCCAGCGAGTTCAAG-3′. Primers were engineered
to contain EcoRI and BamHI restriction sites (in
italics), respectively. The DNA fragment was gel purified, restricted
with BamHI and EcoRI, and subcloned into pSKAC,
creating pSKAC/AQP1as. Left end DNA fragments containing AQP1 sense or
antisense DNA were liberated from pSKAC after restriction with PmeI and XbaI.
Approximately 100 ng of appropriate gel-purified left-end fragment of
AQP1(s) AV or AQP1(as) AV was ligated to approximately 1 μg of the
right-end fragment overnight at 16°C, using T4 ligase (Gibco BRL,
Gaithersburg, MD). The ligation mixture was transfected into single
60-mm dishes of strain 293 human embryonic kidney cells (293 cells)
using lipofectamine reagent (Gibco). Transfected cells were allowed to
lyse without an agar overlay. Cell lysates were subjected to three
rounds of freezing-thawing using a dry ice-ethanol bath. Individual
viruses were isolated from cell lysates by two consecutive rounds of
plaque purification, using an agar overlay.
After isolation, individual viruses were amplified in EBNA-293 cells
(293 cells constitutively expressing EBNA-1 protein from Epstein-Barr
virus; Invitrogen, San Diego, CA). EBNA 293 cells on forty 150-mm
plates (at ∼50% confluence) were infected with appropriate AV at a
multiplicity of infection (MOI) of 3. When the majority of cells were
floating (36–48 hours after infection), the cells were harvested by
gentle scraping and collected by a 5-minute centrifugation at
1000g. The cell pellet was resuspended in 20 mM Tris-HCl and
2 mM EDTA (pH 7.4) and the cells were homogenized with 20 strokes
(Dounce homogenizer; Kontes Glass, Vineland, NJ). RNase A was added to
100 μg/ml, and the homogenate was incubated at 22°C for 5 minutes.
Nuclei were removed by centrifugation at 2500g for 10
minutes. CsCl was added to the supernatant to 0.3 g/ml and the
supernatant layered atop a CsCl step gradient (1.3 and 1.4 g/ml in
virus storage buffer [VSB]: 137 mM NaCl, 20 mM Tris-HCl, 5 mM KCl,
and 1 mM MgCl2 [pH 7.4]) and centrifuged for 2
hours at 30,000 rpm (TH64 rotor; Sorvall, Newtown, CT). The virus band
that formed at the 1.3- to 1.4-g/ml interface was removed with a
16-gauge needle and layered atop a 2-ml bed of Sepharose
(Amersham Pharmacia Biotech, Piscataway, NJ) and centrifuged for 2
minutes at 1000 rpm in a tabletop centrifuge (Beckman Coulter,
Fullerton, CA). This step was repeated once more, and the virus
concentration was adjusted to 1 × 1011 plaque forming units (PFU)/ml in VSB. Sucrose was added to 10% (final
concentration) and the virus preparation was stored in aliquots at−
80°C. Each aliquot was used a maximum of two times and discarded.
Individual AV DNA titers were determined by three methods: (1) plaque
titration on 293 cells, (2) immunofluorescence microscopy of AV protein
expression (anti-penton group antigen, clone 143; Biodesign,
Saco, ME) in 293 cells infected with serial dilutions of AV,
and (3) absorbance (A) at 260 nm (plaque forming units per
milliliter = A260 × dilution ×
1010). Infection of cells with AV is expressed as
MOI, indicating number of infective virus particles per cell. A range
of titers was used to functionally test novel AQP1 AV constructs and
was dependent on the specific requirements of a particular assay.